{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:38:07Z","timestamp":1792762687775,"version":"4.5.0"},"reference-count":32,"publisher":"Pan African Medical Journal","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pan Afr Med J"],"abstract":"<jats:p>La progression de l'ad\u00e9nocarcinome prostatique (CaP) vers la r\u00e9sistance \u00e0 la castration implique des d\u00e9r\u00e8glements mol\u00e9culaires complexes. Cette \u00e9tude \u00e9value l'implication de NF-\u03baB et des r\u00e9cepteurs \u00e0 l'EGF (EGFR, HER3) dans l'agressivit\u00e9 tumorale chez des patients marocains. Une \u00e9tude r\u00e9trospective avec analyse immunohistochimique a \u00e9t\u00e9 r\u00e9alis\u00e9e sur les tissus de 88 patients atteints de CaP. L'expression des sous-unit\u00e9s de NF-\u03baB (p65, p50, RelB), de l'EGFR et de HER3 a \u00e9t\u00e9 corr\u00e9l\u00e9e au statut de r\u00e9sistance \u00e0 la castration et au score de Gleason (tests du Chi-carr\u00e9 et r\u00e9gression logistique). Une forte localisation nucl\u00e9aire de NF-\u03baB a \u00e9t\u00e9 observ\u00e9e dans les cellules canc\u00e9reuses r\u00e9sistantes \u00e0 la castration (p = 0,0005), constituant un marqueur pr\u00e9dictif de progression. Parall\u00e8lement, une surexpression de l'EGFR a \u00e9t\u00e9 identifi\u00e9e chez les patients hormono-r\u00e9fractaires (OR = 5,37; p = 0,0010). L'expression nucl\u00e9aire de HER3 \u00e9tait significativement corr\u00e9l\u00e9e \u00e0 un grade de Gleason \u00e9lev\u00e9 (\u2265 7) dans les tumeurs r\u00e9sistantes (p = 0,0064). L'activation nucl\u00e9aire de NF-\u03baB et de HER3, ainsi que la surexpression de l'EGFR, jouent un r\u00f4le cl\u00e9 dans l'\u00e9volution vers l'\u00e9chappement hormonal. Ces mol\u00e9cules repr\u00e9sentent des cibles th\u00e9rapeutiques et des biomarqueurs pronostiques prometteurs pour la prise en charge du CaP \u00e0 haut risque au Maroc.<\/jats:p>","DOI":"10.11604\/pamj.2026.53.144.51276","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:46:27Z","timestamp":1792759587000},"source":"Crossref","is-referenced-by-count":0,"title":["Expression de NF-\u03baB, EGFR et HER3 dans l\u00b4ad\u00e9nocarcinome prostatique r\u00e9sistant \u00e0 la castration: \u00e9tude clinique et mol\u00e9culaire chez 88 patients marocains"],"prefix":"10.11604","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8327-9745","authenticated-orcid":false,"given":"Ilham","family":"Sadaoui","sequence":"first","affiliation":[{"name":"Laboratoire de Biologie Cellulaire et G\u00e9n\u00e9tique Mol\u00e9culaire (LBCGM), Facult\u00e9 des Sciences, Universit\u00e9 Ibn Zohr, Agadir, Maroc"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane","family":"Sadaoui","sequence":"additional","affiliation":[{"name":"D\u00e9partement des Sciences Informatiques, Universit\u00e9 Al Akhawayn, Ifrane, Maroc"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanaa Amrani","family":"Hassani Joutei","sequence":"additional","affiliation":[{"name":"Laboratoire d'Anatomie et Cytologie Pathologiques de l'Institut Pasteur du Maroc, Casablanca, Maroc"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakima","family":"Benomar","sequence":"additional","affiliation":[{"name":"Laboratoire d'Anatomie et Cytologie Pathologiques de l'Institut Pasteur du Maroc, Casablanca, Maroc"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sellama","family":"Nadifi","sequence":"additional","affiliation":[{"name":"Laboratoire de G\u00e9n\u00e9tique M\u00e9dicale, Facult\u00e9 de M\u00e9decine et de Pharmacie, Casablanca, Maroc"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4870","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"ref0","unstructured":"Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer; 2024. Google Scholar"},{"key":"ref1","unstructured":"Fondation Lalla Salma. REGISTRE DES CANCERS DE LA REGION DU GRAND CASABLANCA. Rapport d'Incidence 2013-2017. Consult\u00e9 le 26 janvier 2026."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Fournier G, Valeri A, Mangin P, Cussenot O. Cancer de la prostate. Traitement [Prostate cancer. Treatment]. Ann Urol (Paris). 2004 Oct;38(5):225-58. French. PubMed | Google Scholar","DOI":"10.1016\/j.anuro.2004.06.004"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Gandaglia G, Karakiewicz PI, Abdollah F, Sun M, Schiffmann J, Trudeau V et al. The effect of age at diagnosis on prostate cancer mortality: a grade-for-grade and stage-for-stage analysis. Eur J Surg Oncol. 2014 Dec;40(12):1706-15. PubMed | Google Scholar","DOI":"10.1016\/j.juro.2014.02.976"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Ferrand FR, Pavic M. Traitements ciblant la voie du r\ufffdcepteur aux androg\ufffdnes dans le cancer de la prostate [Therapeutic targeted approaches on androgen receptors in prostate cancer]. Rev Med Interne. 2014 Oct;35(10):670-5. French. PubMed | Google Scholar","DOI":"10.1016\/j.revmed.2014.05.012"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001 Oct;1(1):34-45. PubMed | Google Scholar","DOI":"10.1038\/35094009"},{"key":"ref6","unstructured":"Di Lorenzo G, Tortora G, D'Armiento FP, De Placido S, Gallo C, Bianco R et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res. 2002 Nov;8(11):3438-44. PubMed | Google Scholar"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"McDonnell TJ, Chari NS, Cho-Vega JH, Huang PS, Wang S, Do KA et al. Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer. BMC Med Genomics. 2008 Jan 31;1:1. PubMed | Google Scholar","DOI":"10.1186\/1755-8794-1-1"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Xu Y, Josson S, Fang F, Hayden MS, Spector NL, Gurlo T et al. RelB enhances prostate cancer growth: implications for the role of the nuclear factor-kappaB alternative pathway in tumorigenicity. Cancer Res. 2009 Apr 15;69(8):3267-71. PubMed | Google Scholar","DOI":"10.1158\/0008-5472.CAN-08-4635"},{"key":"ref9","unstructured":"Ogunbiyi JO, Shittu OB. Increased incidence of prostate cancer in Nigerians. J Natl Med Assoc. 1999 Mar;91(3):159-64. PubMed | Google Scholar"},{"key":"ref10","unstructured":"Peko JF, Bouya P, Kokolo J, Ngolet A. Cancers de la prostate au CHU de Brazzaville: Epid\ufffdmiologie et histo-pronostic. 2003. Consult\u00e9 le 26 janvier 2026."},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol. 1994 Nov;152(5 Pt 2):1714-20. PubMed | Google Scholar","DOI":"10.1016\/S0022-5347(17)32369-8"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Samtal C, Bouguenouch L, Ismaili N, El Baldi M, El Makhzen B, El Rhazi K. Update on prostate cancer epidemiology in Morocco. African Journal of Urology. 2024 Apr 27;30(1):22. Google Scholar","DOI":"10.1186\/s12301-024-00419-0"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Ploussard G, Dariane C, Mathieu R, Baboudjian M, Barret E, Brureau L et al. Comit\u00e9 de Canc\u00e9rologie de l\u00b4Association Fran\u00e7aise d\u00b4Urologie, Groupe Prostate, Maison de l\u00b4Urologie. French AFU Cancer Committee Guidelines - Update 2024-2026: Prostate cancer - Management of metastatic disease and castration resistance. Fr J Urol. 2024 Nov;34(12):102710. PubMed | Google Scholar","DOI":"10.1016\/j.fjurol.2024.102710"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Staal J, Beyaert R. Inflammation and NF-\u03baB Signaling in Prostate Cancer: Mechanisms and Clinical Implications. Cells. 2018 Aug 29;7(9):122. PubMed | Google Scholar","DOI":"10.3390\/cells7090122"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Grosset AA, Ouellet V, Caron C, Trudel D, Labb\u00e9 DP, Froehlich U et al. Validation of the prognostic value of NF-\u03baB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network. PLoS Med. 2019 Jul 2;16(7):e1002847. PubMed | Google Scholar","DOI":"10.1371\/journal.pmed.1002847"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Koumakpayi IH, Diallo JS, Le Page C, Lessard L, Gauthier PJ, Paquin A et al. Expression and nuclear localization of ErbB3 in prostate cancer. Clin Cancer Res. 2006 May 1;12(9):2730-7. PubMed | Google Scholar","DOI":"10.1158\/1078-0432.CCR-05-2242"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Diallo JS, Betton B, Parent N, Gaumond JP, Abbas-Terki T, Guisset AC et al. Enhanced killing of androgen-independent prostate cancer cells using inositol hexakisphosphate in combination with proteasome inhibitors. Br J Cancer. 2008 Nov 18;99(10):1613-22. PubMed | Google Scholar","DOI":"10.1038\/sj.bjc.6604730"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Bouraoui Y, Ben Jemaa A, Rodriguez G, Casabianca JM, Gion M, Hannaoui N et al. Profile of NF-\u03baBp (65\/NF\u03baBp50) among prostate specific antigen sera levels in prostatic pathologies. Pathol Biol (Paris). 2012 Oct;60(5):301-5. PubMed | Google Scholar","DOI":"10.1016\/j.patbio.2011.07.007"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Cansino JR, Vera R, Rodr\u00edguez F, Tabernero A, Cisneros J, de la Pe\u00f1a JJ et al. Ant\u00edgeno prost\u00e1tico espec\u00edfico y NF-kB en la patolog\u00eda prost\u00e1tica: [Prostate specific antigen and NF-kB in prostatic disease: relation with malignancy]. Actas Urol Esp. 2011 Jan;35(1):16-21. Spanish. PubMed | Google Scholar","DOI":"10.1016\/j.acuro.2010.08.002"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Yu H, Lin L, Zhang Z, Zhang H, Hu H. Targeting NF-\u03baB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct Target Ther. 2020 Sep 21;5(1):209. PubMed | Google Scholar","DOI":"10.1038\/s41392-020-00312-6"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Ismail HA, Lessard L, Mes-Masson AM, Saad F. Expression of NF-kappaB in prostate cancer lymph node metastases. Prostate. 2004 Feb 15;58(3):308-13. PubMed | Google Scholar","DOI":"10.1002\/pros.10335"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Lessard L, Karakiewicz PI, Bellon-Gagnon P, Paquin A, Mes-Masson AM, Saad F. Nuclear localization of p65 highly predictive of pelvic lymph node metastases. Clin Cancer Res. 2006 Oct;12(19):5741-5. PubMed | Google Scholar","DOI":"10.1158\/1078-0432.CCR-06-0330"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Domingo-Domenech J, Mellado B, Ferrer B, Truan D, Codony-Servat J, Sauleda S et al. Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer. 2005 Nov 28;93(11):1285-94. PubMed | Google Scholar","DOI":"10.1038\/sj.bjc.6602851"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol. 2008 Aug;8(4):440-8. PubMed | Google Scholar","DOI":"10.1016\/j.coph.2008.07.005"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Cho KS, Lee JS, Cho NH, Park K, Ham WS, Choi YD. Gene amplification and mutation analysis of epidermal growth factor receptor in hormone refractory prostate cancer. Prostate. 2008 Jun 1;68(8):803-8. PubMed | Google Scholar","DOI":"10.1002\/pros.20743"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Le Page C, Koumakpayi IH, Lessard L, Mes-Masson AM, Saad F. EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells. Prostate. 2005 Oct 1;65(2):130-40. PubMed | Google Scholar","DOI":"10.1002\/pros.20234"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Krop IE, Masuda N, Mukohara T, Matsuaru K, Bazhenova L, Kim SB et al. Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I\/II Trial. J Clin Oncol. 2023 Dec 20;41(36):5550-5560. PubMed | Google Scholar","DOI":"10.1200\/JCO.23.00882"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Gu\u00e9rin O, Fischel JL, Ferrero JM, Bozec A, Milano G. EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment. Pharmaceuticals (Basel). 2010 Jul 19;3(7):2238-2247. PubMed | Google Scholar","DOI":"10.3390\/ph3072238"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Seo SI, Song SY, Kang MR, Kim MS, Oh JE, Kim YR, et al. Immunohistochemical analysis of NF-kappaB signaling proteins IKKepsilon, p50\/p105, p52\/p100 and RelA in prostate cancers. APMIS. 2009 Aug;117(8):623-8. PubMed | Google Scholar","DOI":"10.1111\/j.1600-0463.2009.02506.x"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Miranda S, Gil V, Riisnaes R, Gurel B, Bertan C, Nava Rodrigues D et al. HER3 Is an Actionable Target in Advanced Prostate Cancer. Cancer Res. 2021 Dec 15;81(24):6207-6218. PubMed | Google Scholar","DOI":"10.1158\/0008-5472.CAN-21-3360"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Koumakpayi IH, Diallo JS, Le Page C, Lessard L, Gauthier PJ, Paquin A et al. Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer. BJU Int. 2007 Aug;100(2):303-9. PubMed | Google Scholar","DOI":"10.1111\/j.1464-410X.2007.06992.x"}],"container-title":["Pan African Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:46:31Z","timestamp":1792759591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.panafrican-med-journal.com\/content\/article\/53\/144\/full\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":32,"URL":"https:\/\/doi.org\/10.11604\/pamj.2026.53.144.51276","relation":{},"ISSN":["1937-8688"],"issn-type":[{"value":"1937-8688","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]}}}